SCHEDULE: Deep Track Capital Divests Entire Pliant Therapeutics Stake
Schedule 13G Amendment
Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in Pliant Therapeutics, Inc., holding 0% of the common stock.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an Amendment No. 3 to Schedule 13G regarding their holdings in Pliant Therapeutics, Inc.
- The filing indicates that as of September 30, 2025, the reporting persons beneficially own 0 shares of Pliant Therapeutics, Inc. common stock.
- This represents 0% of the class of securities, calculated based on 61,388,154 common shares outstanding as of August 1, 2025, as reported in the issuer's 10-Q filed on August 7, 2025.
- This amendment signifies a complete divestment of their previous holdings in the company.
Sentiment
Score: 3
Explanation: The complete divestment by Deep Track Capital, a specialized biotechnology investor, suggests a negative outlook or a strategic shift away from Pliant Therapeutics, which can be perceived negatively by the market.
Negatives
- A significant institutional investor, Deep Track Capital and its affiliates, has completely divested its stake in Pliant Therapeutics, Inc.
Risks
- The complete divestment by a specialized institutional investor could signal a lack of confidence in Pliant Therapeutics' future prospects or a change in investment strategy, potentially impacting investor sentiment and stock price.
Future Outlook
NA
Industry Context
The divestment by a specialized biotechnology fund like Deep Track Capital could reflect a shift in sector-specific investment theses or concerns about a particular company's pipeline or market position within the biotech industry. Such moves by institutional investors are closely watched for signals regarding industry trends or company-specific challenges.
Stakeholder Impact
- Shareholders may view the complete divestment by a significant institutional investor as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| August 1, 2025 | Date used for calculating the number of common shares outstanding (61,388,154 shares). |
| August 7, 2025 | Date Pliant Therapeutics' 10-Q was filed with the SEC, providing the shares outstanding data. |
| September 30, 2025 | Date of the event which required the filing of this statement, indicating the beneficial ownership changed to 0%. |
| November 14, 2025 | Filing date of this Schedule 13G Amendment No. 3. |
Recommendation
sellThe complete divestment by a specialized institutional investor like Deep Track Capital, particularly as an Amendment No. 3 indicating a full exit, often signals a loss of confidence or a strategic decision to reallocate capital away from the company. This could precede further negative sentiment or price declines, making a 'sell' recommendation prudent for existing holders or advising against new positions.
Keywords
Pliant Therapeutics, Deep Track Capital, Schedule 13G, Beneficial Ownership, Divestment, Biotechnology, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.